Cancer is one of India's leading health challenges, and while most cancers are not inherited, certain mutations can significantly increase your lifetime risk. Genetic testing offers a way to understand your personal and family cancer risk by examining your DNA.
Genetic testing for cancer risk assessment does not diagnose cancer. It answers a narrower, more useful question: does your DNA carry a mutation that raises your lifetime odds of developing certain cancers, and if so, what should you and your doctor do differently because of it? For families with a strong cancer history, or for anyone diagnosed with cancer at an unusually young age, that answer can reshape screening schedules, surgical decisions, and even choices made on behalf of children and siblings.
This guide walks through who actually needs testing, how the process works from counselling to results, what a positive, negative, or inconclusive result really means, and how a cancer centre like BMH's NAVA Cancer Institute builds risk assessment into a full care pathway rather than treating it as a one-off lab report.
What Is Genetic Testing for Cancer Risk Assessment?
Genetic testing for cancer risk is a blood or saliva test that examines your DNA for inherited mutations linked to higher cancer risk. Unlike tests that diagnose cancer you already have, risk assessment testing identifies whether you carry genes that can make cancer more likely over your lifetime.
The most well-known examples include the BRCA1 and BRCA2 genes, which significantly increase the risk of breast and ovarian cancers in women, and prostate cancer in men. Other genes, such as Lynch syndrome genes and CDH1, are associated with different cancer types.
Germline Testing vs. Somatic (Tumour) Testing
Germline testing looks at DNA present in every cell of your body, inherited from a parent, this is what's used for hereditary cancer risk assessment. Somatic or tumour testing, by contrast, analyses mutations that exist only inside cancer cells and is used to guide treatment choice in someone already diagnosed. The two are often confused, but they answer completely different clinical questions and use different samples.
Who Should Consider Genetic Testing for Cancer Risk?
Genetic testing isn't recommended for everyone, it's targeted at people whose personal or family history raises a reasonable suspicion of an inherited mutation. Oncology bodies such as the National Comprehensive Cancer Network (NCCN) use a set of 'red flag' criteria to identify who should be offered pre-test counselling.
| Red-Flag Indicator | Why It Matters | Genes Often Involved |
|---|---|---|
| Cancer diagnosed before age 45–50 | Early onset is a classic hereditary-cancer signal | BRCA1/2, MLH1, MSH2 |
| 2+ relatives on the same side with related cancers | Pattern suggests a shared inherited variant | BRCA1/2, Lynch genes |
| Ovarian, pancreatic, or male breast cancer at any age | These cancers are strongly linked to hereditary syndromes | BRCA1/2, PALB2 |
| Triple-negative breast cancer before age 60 | Higher likelihood of an underlying BRCA1 mutation | BRCA1 |
| Multiple primary cancers in one person | Suggests a broader cancer-predisposition syndrome | TP53, Lynch genes |
| A known mutation already identified in the family | Relatives can be tested for that exact variant | Depends on family |
Common Hereditary Cancer Genes and Syndromes
Several inherited gene mutations are known to increase the lifetime risk of developing certain cancers. Identifying these hereditary cancer syndromes through genetic testing can help guide earlier screening, preventive measures, and treatment decisions for both patients and their family members.
1. BRCA1 and BRCA2: Hereditary Breast and Ovarian Cancer (HBOC)
BRCA1 and BRCA2 are the most widely recognised hereditary cancer genes. Population studies estimate the average cumulative risk of breast cancer in a BRCA1 carrier at around 65% by age 70, and around 45% for BRCA2 carriers; ovarian cancer risk is estimated at roughly 39% for BRCA1 and 11% for BRCA2 by the same age. BRCA2 mutations are also linked to a notably increased risk of male breast cancer.
2. Lynch Syndrome
Caused by mutations in mismatch-repair genes, MLH1, MSH2, MSH6, and PMS2, Lynch syndrome is the most common inherited cause of colorectal cancer and also raises the risk of endometrial, gastric, ovarian, urinary tract, and other cancers. It's typically suspected when colorectal or endometrial cancer occurs before age 50, or runs across multiple generations of a family.
Other Genes Worth Knowing
- TP53: Linked to Li-Fraumeni syndrome, associated with a broad range of early-onset cancers
- PALB2 and ATM: Moderate-to-high risk genes for breast and pancreatic cancer
- CHEK2: A moderate-risk gene for breast and colorectal cancer
- APC: Causes Familial Adenomatous Polyposis (FAP), a strong colorectal cancer risk syndrome
How Does the Testing Process Work?
Genetic testing is a structured process that combines expert counselling, laboratory analysis, and careful interpretation of results. Each step is designed to ensure the test is appropriate, the findings are accurately understood, and the results can be used to guide future screening, prevention, or treatment decisions.
Step 1: Pre-Test Genetic Counselling
Before any sample is collected, a genetic counsellor or oncologist reviews your personal and three-generation family cancer history, explains what a multigene panel can and cannot tell you, and discusses the emotional and practical implications of each possible result. This step is not a formality, it's what determines whether testing is even appropriate, and which panel of genes makes sense for your specific history.
Step 2: Sample Collection and Multigene Panel Analysis
Testing typically requires only a blood draw or saliva sample. Modern labs use next-generation sequencing (NGS) to screen dozens of cancer-predisposition genes simultaneously in a single multigene panel, rather than testing one gene at a time, this has made comprehensive testing faster and considerably more affordable than it was a decade ago.
Step 3: Interpreting Results
Results generally fall into one of three categories, and the difference between them matters a great deal for what happens next:
- Positive: a known pathogenic (disease-causing) mutation is identified
- Negative: no mutation found in the genes tested (this does not rule out all hereditary risk, especially if no mutation has been identified elsewhere in the family)
- Variant of Uncertain Significance (VUS): a genetic change was found, but current evidence isn't enough to classify it as harmful or harmless; VUS classifications are often revisited and updated as research evolves.
What Your Results Mean And What Happens Next
Genetic test results fall into three main categories: positive (a mutation linked to increased cancer risk is found), negative (no known cancer-risk mutation is detected), and uncertain or variant of uncertain significance (a change in DNA is found but its cancer risk impact is not yet clear).
If You Test Positive
A positive result opens up a set of evidence-based options rather than a single fixed path: more frequent or earlier screening (such as annual breast MRI alongside mammography from a younger age), chemoprevention medication in some cases, and, for some high-risk individuals, risk-reducing surgery. Just as importantly, first-degree relatives, parents, siblings, and children, of a confirmed carrier have up to a 50% chance of carrying the same mutation, which is why genetic counsellors strongly encourage cascade testing across the family once a variant is identified.
If You Test Negative
A negative result is reassuring, but its meaning depends on context. If a specific mutation has already been identified elsewhere in your family and you test negative for that exact variant, your risk returns close to the general population level. If no family mutation is known and you test negative on a broad panel, some inherited risk still cannot be fully ruled out, and standard age-based screening guidelines continue to apply.
If You Get a Variant of Uncertain Significance
A VUS is not a green light or a red flag, it's an open question. Most VUS findings are eventually reclassified as benign as more population data becomes available. Genetic counsellors typically recommend continuing standard screening based on family history alone until a VUS is reclassified, rather than making major medical decisions based on it.
Why Choose Baby Memorial Hospital for Hereditary Cancer Risk Assessment?
Genetic testing is most valuable when it leads to a clear prevention or treatment plan. At NAVA Cancer Institute, Baby Memorial Hospital (BMH), hereditary cancer risk assessment is integrated into a multidisciplinary oncology pathway, allowing genetic findings to inform personalised screening, surveillance, and treatment decisions.
Why patients choose BMH:
-
Comprehensive cancer care through NAVA Cancer Institute, with medical, surgical, radiation, and hemato-oncology specialists working together.
-
Advanced diagnostics and treatment including TrueBeam image-guided radiotherapy, Da Vinci robotic surgery, brachytherapy, targeted therapy, immunotherapy, and bone marrow transplant services.
-
Multidisciplinary tumour boards that incorporate genetic test results into individualised cancer prevention and treatment strategies.
-
Dedicated preventive screening programmes, including NAVAyug Cancer Screening for both men and women, designed to detect cancer at earlier, more treatable stages.
Book your NAVAyug Cancer Screening at Baby Memorial Hospital today to understand your cancer risk, detect disease early, and receive a personalised screening plan based on your health and family history.
Also Read: Recommended Cancer Screening Tests for Every Adults
Common Myths About Genetic Testing for Cancer Risk: Debunked
-
"If I test positive, I will definitely get cancer." False, a positive result raises risk; it does not guarantee cancer will develop.
-
"A negative result means I have no cancer risk at all." False, it lowers risk related to the genes tested, but general population risk and lifestyle factors still apply.
-
"Genetic testing is only for people who already have cancer." False, risk-assessment testing is most valuable before a cancer diagnosis, so screening and prevention can start earlier.
-
"One test covers every type of cancer." False, panels are selected based on personal and family history; no single panel screens for all hereditary cancer syndromes.
-
"Results are private from insurers and employers." This varies significantly by country and policy, it's worth discussing data privacy specifically during pre-test counselling.
Conclusion
Genetic testing for cancer risk assessment isn't about predicting the future with certainty, it's about replacing guesswork with a clearer, evidence-based picture of your inherited risk, so screening, prevention, and family conversations can happen earlier and on better information.
For the roughly two-thirds of at-risk women who, per national data, still haven't had this conversation with a doctor, and for Indian families where BRCA and Lynch-related mutations are more common than often assumed, the first step is simply a conversation with a genetic counsellor or oncologist about whether your history meets the criteria for testing.
If you're trying to work out whether that applies to you or someone in your family, BMH's oncology team at NAVA Cancer Institute can help you think through your family history and next steps, you can chat with our care assistant on the BMH website to get a conversation started.
Medical Disclaimer This article is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Genetic testing decisions should always be made in consultation with a qualified genetic counsellor or physician who can evaluate your personal and family history. Always seek the advice of your doctor or another qualified health provider with any questions you may have regarding a medical condition or genetic testing.